1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl} propanedioate | 867367-05-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl} propanedioate
• 英文别名: 1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl}propanedioate；3-O-tert-butyl 1-O-ethyl 2-[3-(3-chloro-5-cyanophenoxy)-2-fluoro-4-nitrophenyl]propanedioate
• CAS: 867367-05-3
• 化学式: C₂₂H₂₀ClFN₂O₇
• 分子量: 478.861
• InChiKey: QCVJWFYIXUDLIG-UHFFFAOYSA-N

物化性质

• 沸点：
  516.0±50.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl} propanedioate 在 亚硝酸特丁酯 、 sodium dithionite 、 三氟乙酸 、 copper(I) bromide 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 4.0h， 生成 2-{4-溴-3-[(3-氯-5-氰基苯基)氧基]-2-氟苯基}乙酰肼
  参考文献：
  名称：

  WO2008/157330

  摘要：

  公开号：
• 作为产物：
  描述：

  3,5-二氯苯腈 在 2,4,6-三甲基吡啶 、 sodium hydride 、 lithium iodide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 13.0h， 生成 1,1-dimethylethyl ethyl {3-[(3-chloro-5-cyanophenyl)oxy]-2-fluoro-4-nitrophenyl} propanedioate
  参考文献：
  名称：

  WO2008/157330

  摘要：

  公开号：

文献信息

• Heterocyclic antiviral compounds
  申请人：Dunn Patrick James

  公开号：US20060025462A1

  公开（公告）日：2006-02-02

  The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R 1 , R 2 , R 3 , R 4 , R 5 , are as defined herein.

  本发明涉及一种符合式I的化合物，通过给予符合式I的化合物治疗由人类免疫缺陷病毒介导的疾病的方法，以及用于治疗由人类免疫缺陷病毒介导的疾病的药物组合物，其中R1、R2、R3、R4、R5如本文所定义。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Roche Palo Alto LLC

  公开号：US20040198736A1

  公开（公告）日：2004-10-07

  This invention relates to novel pyridazinone derivatives of formula I wherein R 1 -R 4 , R 7 , R 8 and X 1 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficiency Virus (HIV) reverse transcriptase with compounds of formula I, pharmaceutical compositions containing of formula I admixed with at least one solvent, carrier or excipient and processes to prepare compounds of formula I. The compounds are useful for treating disorders in which HIV and genetically related viruses are implicated 1

  这项发明涉及公式I的新型吡啶并酮衍生物，其中R1-R4、R7、R8和X1如摘要中所定义，并且其药学上可接受的盐和溶剂化合物，用公式I的化合物抑制或调节人类免疫缺陷病毒（HIV）逆转录酶的方法，含有公式I的药物组合物与至少一种溶剂、载体或赋形剂混合，并制备公式I的化合物的方法。这些化合物可用于治疗HIV和遗传相关病毒参与的疾病。
• Process for preparing pyridazinone compounds
  申请人：Kertesz John Denis

  公开号：US20050234236A1

  公开（公告）日：2005-10-20

  The present invention provides a process for the preparation 6-[3-(hetero)aryloxy-2-fluoro-benzyl]-2H-pyridazin-3-one compounds 1 where R2 is an optionally substituted aryl or an optionally substituted heteroaryl, R 6 is NO 2 , NH 2 , alkyl, halogen, or a function group readily derived therefrom and R 4c is hydrogen or alkyl. There also is provided a process for the preparation of phenylacetic acid compounds 2, wherein R 2 and R 6 are as defined previously and R 5a is hydrogen or alkyl, which are useful for the preparation of pyridazinone compounds.

  本发明提供了一种制备6-[3-(杂)芳氧基-2-氟苯甲基]-2H-吡啶嗪-3-酮化合物1的方法，其中R2为可任选取代的芳基或可任选取代的杂芳基，R6为NO2、NH2、烷基、卤素或易于由此衍生的功能团，R4c为氢或烷基。本发明还提供了一种制备苯乙酸化合物2的方法，其中R2和R6如前所述定义，R5a为氢或烷基，这些化合物对于制备吡啶嗪酮化合物是有用的。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Billedeau Roland Joseph

  公开号：US20090170856A1

  公开（公告）日：2009-07-02

  Compounds of formula I, wherein R 1 , R 2 , R 3 , X 1 , X 2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV- 1 infections and the treatment of AIDS and/or ARC.

  式I化合物，其中R1、R2、R3、X1、X2和Ar如本文所定义，或其药学上可接受的盐，抑制HIV-1逆转录酶，并提供预防和治疗HIV-1感染以及治疗艾滋病和/或艾滋病相关复合征（ARC）的方法。本发明还涉及含有式I化合物的组合物，这些组合物对于预防和治疗HIV-1感染以及治疗艾滋病和/或ARC是有用的。
• Design of Annulated Pyrazoles as Inhibitors of HIV-1 Reverse Transcriptase
  作者：Zachary K. Sweeney、Seth F. Harris、Nidhi Arora、Hassan Javanbakht、Yu Li、Jennifer Fretland、James P. Davidson、J. Roland Billedeau、Shelley K. Gleason、Donald Hirschfeld、Joshua J. Kennedy-Smith、Taraneh Mirzadegan、Ralf Roetz、Mark Smith、Sarah Sperry、Judy M. Suh、Jeffrey Wu、Stan Tsing、Armando G. Villaseñor、Amber Paul、Guoping Su、Gabrielle Heilek、Julie Q. Hang、Amy S. Zhou、Jesper A. Jernelius、Fang-Jie Zhang、Klaus Klumpp

  DOI：10.1021/jm800527x

  日期：2008.12.11

  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of HIV. These regimens are extremely effective in suppressing virus replication. Structure-based optimization of diaryl ether inhibitors led to the discovery of a new series of pyrazolo[3,4-c]pyridazine NNRTIs that bind the reverse transcriptase enzyme of human immunodeficiency virus-1 (HIV-RT) in an expanded volume relative to most other inhibitors in this class.The binding mode maintains the beta13 and beta14 strands bearing Pro236 in a position similar to that in the unliganded reverse transcriptase structure, and the distribution of interactions creates the opportunity for substantial resilience to single point mutations. Several pyrazolopyridazine NNRTIs were found to be highly effective against wild-type and NNRTI-resistant viral strains in cell culture.